Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
Article in Journal for ImmunoTherapy of Cancer (April 2024)
The most recent citing publications are shown below. View all 57 publications that cite this research output on Dimensions.
Article in Journal for ImmunoTherapy of Cancer (April 2024)
Article in Frontiers in Immunology (April 2024)
Article in Angewandte Chemie (April 2024)